Actively Recruiting
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2022-06-22
60
Participants Needed
1
Research Sites
240 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
CONDITIONS
Official Title
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years and older
- Able to understand and voluntarily sign informed consent
- Histopathologically confirmed recurrent or metastatic solid tumors
- Prior standard systemic therapy failed, was not tolerated, or no standard therapy exists
- At least one measurable lesion according to RECIST Version 1.1
- At least one superficial or deep lesion suitable for intratumoral injection and biopsy
- Adequate organ function
- ECOG performance status of 0 or 1
- Weight greater than 30 kg
- Expected survival longer than 12 weeks
- Female patients must be postmenopausal or have a negative pregnancy test if of childbearing potential
You will not qualify if you...
- Received systemic anti-tumor therapy within 28 days before first dose
- Radiotherapy within 14 days before first dose
- Use of immunosuppressants
- Major surgery within 28 days before first dose
- Poorly controlled or unstable diseases
- Active autoimmune or inflammatory diseases
- Symptomatic central nervous system tumors or metastases
- Persistent toxicity from prior anti-tumor therapy at grade 2 or higher
- Other cancers within past 5 years except certain cured in situ or superficial cancers
- Active infections
- Any condition increasing risk or affecting study compliance as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Actively Recruiting
Research Team
D
Dawei Wu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here